Polymorphisms in genes such as BCL11A and HBS1L-MYB have been identified as key regulators of HbF production, offering potential targets for therapeutic modulation and personalized management of nephropathy in SCD patients. The gene discussed is HBS1L; the disease is kidney disorder.